Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)
Primary Purpose
SCID, X Linked
Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TYF-IL-2Rg gene-modified autologous stem cells
Sponsored by
About this trial
This is an interventional treatment trial for SCID, X Linked focused on measuring SCID-X1, lentiviral vector
Eligibility Criteria
Inclusion Criteria:
Diagnosis of classical SCID-X1 based on:
- A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
- T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigens.
- With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus or fungus; disseminated BCG infection.
- No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia of children.
- No prior allogeneic stem cell transplantation.
- Life expectancy ≥ 2 months.
- Negative for HIV infection.
- Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
None
Sites / Locations
- Capital Institute of Pediatrics affiliated Children's hospitalRecruiting
- Beijing Children's HospitalRecruiting
- Shenzhen Geno-immune Medical InstituteRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Single arm
Arm Description
Gene transfer to treat SCID-X1
Outcomes
Primary Outcome Measures
Overall survival
Overall immune reconstitution
T and B cell recovery
Change of infection status
Secondary Outcome Measures
Full Information
NCT ID
NCT03217617
First Posted
July 3, 2017
Last Updated
September 18, 2019
Sponsor
Shenzhen Geno-Immune Medical Institute
1. Study Identification
Unique Protocol Identification Number
NCT03217617
Brief Title
Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)
Official Title
Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Unknown status
Study Start Date
July 15, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
December 31, 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Shenzhen Geno-Immune Medical Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a Phase I/II clinical trial of gene transfer for treating X-linked severe combined immunodeficiency (SCID-X1) using a self-inactivating lentiviral vector TYF-IL-2Rg to functionally correct the defective gene(s). The primary objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Detailed Description
X-linked severe combined immunodeficiency (SCID-X1) is a genetic disorder caused by defects in the common cytokine receptor chain, normally on the surface of lymphocytes. Individuals with SCID-X1 lack the normal development of a functional immune system and so have difficulty fighting infections, which may lead to chronic or severe illness and death. X-SCID patients are normally rescued by a bone marrow transplant from a healthy donor. This trial aims to treat SCID-X1 using a self-inactivating lentiviral vector carrying a functional gene to correct the genetic defect. By collecting an individual's stem cells and modifying them with a lentivirus, the gene-corrected cells can be returned into the blood to help produce normal healthy immune cells.
The primary objectives are to evaluate the safety of the self-inactivating lentiviral vector TYF-IL-2Rg, the ex vivo gene transfer clinical protocol and the efficacy of immune reconstitution in patients overcoming frequent infections present at the time of treatment, assessment of integration sites, and finally the long-term correction of immunodeficiency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
SCID, X Linked
Keywords
SCID-X1, lentiviral vector
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Single arm
Arm Type
Experimental
Arm Description
Gene transfer to treat SCID-X1
Intervention Type
Biological
Intervention Name(s)
TYF-IL-2Rg gene-modified autologous stem cells
Intervention Description
Infusion of transduced autologous stem cells
Primary Outcome Measure Information:
Title
Overall survival
Time Frame
1 year
Title
Overall immune reconstitution
Description
T and B cell recovery
Time Frame
1 year
Title
Change of infection status
Time Frame
1 year
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
1 Month
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosis of classical SCID-X1 based on:
A proven mutation in the common gamma chain gene as defined by direct sequencing of patient DNA.
T-cell immune deficiency defined as one or more of the following: CD3+ autologous T cells < 300/ul, or less than 50% of normal value for in vitro mitogen stimulation, or absent proliferation in vitro to antigens.
With severe infections, including but not limited to: pneumonitis; protracted diarrhea requiring total parenteral nutrition; infection with herpes viruses or adenovirus or fungus; disseminated BCG infection.
No cytogenetic abnormalities (medullary karyotype) and no detection of main rearrangements associated with acute leukemia of children.
No prior allogeneic stem cell transplantation.
Life expectancy ≥ 2 months.
Negative for HIV infection.
Written, informed consent obtained prior to any study-specific procedures.
Exclusion Criteria:
None
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lung-Ji Chang, Ph.D
Phone
86-075586725195
Email
c@szgimi.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lung-Ji Chang, Ph.D
Organizational Affiliation
Shenzhen Geno-Immune Medical Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiao-Dong Shi, M.D./Ph. D
Organizational Affiliation
Capital Institute of Pediatrics affiliated Children's hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jie Zheng, M.D./Ph. D
Organizational Affiliation
Beijing Children's Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Capital Institute of Pediatrics affiliated Children's hospital
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100020
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
XiaoDong Shi, M.D./P.H.D
Phone
+86-13911601076
Email
xsusan28@sina.com
First Name & Middle Initial & Last Name & Degree
Lixiao Shi, M.M.
Phone
+86-18810963129
Email
13780524314@163.com
Facility Name
Beijing Children's Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jie Zheng, MD/PhD
Phone
+86-13683284467
Email
cutezjie@163.com
Facility Name
Shenzhen Geno-immune Medical Institute
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lung-Ji Chang, PhD
Phone
86-075586725195
Email
c@szgimi.org
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector (TYF-IL-2Rg)
We'll reach out to this number within 24 hrs